

Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma


<https://doi.org/10.1038/s41586-023-05892-1>

Published online: 9 March 2023

Correction to: *Nature* <https://doi.org/10.1038/s41586-022-05368-8>

Published online 26 October 2022

Open access

 Check for updates

Rodabe N. Amaria, Michael Postow, Elizabeth M. Burton, Michael T. Tetzlaff, Merrick I. Ross, Carlos Torres-Cabala, Isabella C. Glitza, Fei Duan, Denái R. Milton, Klaus Busam, Lauren Simpson, Jennifer L. McQuade, Michael K. Wong, Jeffrey E. Gershenwald, Jeffrey E. Lee, Ryan P. Goepfert, Emily Z. Keung, Sarah B. Fisher, Allison Betof-Warner, Alexander N. Shoushtari, Margaret Callahan, Daniel Coit, Edmund K. Bartlett, Danielle Bello, Parisa Momtaz, Courtney Nicholas, Aidi Gu, Xuejun Zhang, Brinda Rao Korivi, Madhavi Patnana, Sapna P. Patel, Adi Diab, Anthony Lucci, Victor G. Prieto, Michael A. Davies, James P. Allison, Padmanee Sharma, Jennifer A. Wargo, Charlotte Ariyan & Hussein A. Tawbi

In the version of this article initially published, the surname of author Michael T. Tetzlaff was misspelled as ‘Tezlaff.’ In addition, the Acknowledgements section omitted mention of grant P50CA221703 from the National Cancer Institute of the National Institutes of Health, which supported the work. The errors have been corrected in the HTML and PDF versions of the article.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023